Back to top
more

Eagle Pharmaceuticals (EGRX)

(Delayed Data from OTC)

$0.65 USD

0.65
3,941

-0.05 (-7.17%)

Updated Nov 15, 2024 03:51 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks News

New Strong Sell Stocks for March 1st

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

    MedTech Thriving on Consolidation & Expansion: Stocks to Buy

    The industry has some powerful long-term tailwinds of the medical device industry like mergers & acquisitions (M&A), emerging market expansion, positive demographic trends and new product innovation.

      Arpita Dutt headshot

      Key FDA Events to Watch Out for in Jul 2017

      Will the FDA follow the advice of its advisory panel and give its nod to Puma's (PBYI) neratinib?

        What Falling Estimates & Price Mean for Eagle Pharmaceuticals (EGRX)

        Eagle Pharmaceuticals (EGRX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

          MedTech Stocks' Q4 Earnings on Mar 1: ICUI, GKOS & EGRX

          Let's take a look at the major MedTech stocks within the broader medical community, slated to release their reports on Mar 1.

            Falling Earnings Estimates Signal Weakness Ahead for Eagle Pharmaceuticals (EGRX)

            Eagle Pharmaceuticals (EGRX) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.

              Eagle Pharmaceuticals Wraps Up Ryanodex NDA Submission

              Eagle (EGRX) announced that it has completed the submission of its 505(b)(2) NDA in the U.S. for Ryanodex for the treatment of exertional heat stroke.

                Quest Diagnostics: Strong Q3, Strategic Initiatives Add Value

                On Dec 27, 2016, we issued an updated research report on Quest Diagnostics, Inc. (DGX).

                  Myriad Genetics' Unit Releases Favorable Data on Vectra DA

                  Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience released favorable data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA).

                    Tirthankar Chakraborty headshot

                    New Strong Buy Stocks for December 16th

                    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

                      Tirthankar Chakraborty headshot

                      New Strong Buy Stocks for November 30th

                      Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

                        The Zacks Analyst Blog Highlights: Best Buy, Edgewell Personal Care and Eagle Pharma

                        The Zacks Analyst Blog Highlights: Best Buy, Edgewell Personal Care and Eagle Pharma

                          Tirthankar Chakraborty headshot

                          New Strong Buy Stocks for November 15th

                          Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

                            Company News for November 10, 2016

                            Companies in the News are: BDSI,DISH,EGRX,HCAP